Form 4: Neogenomics Director Michael Kelly Reports Stock Option and Restricted Stock Unit Acquisition
SEC Form 4 Filing
Director Michael Aaron Kelly reports acquisition of stock options and restricted stock units in Neogenomics Inc.
Summary
- On June 4, 2024, Michael Aaron Kelly, a director of Neogenomics Inc., filed a Form 4.
- The report details changes in his beneficial ownership of Neogenomics securities.
- Kelly acquired 8,672 stock options with an exercise price of $13.71 on June 1, 2024, exercisable from June 1, 2025, and expiring on June 1, 2034.
- He also acquired 12,254 restricted stock units on June 1, 2024, which vest starting June 1, 2025.
- Kelly directly owns 20,419 shares of common stock.
- He also holds various stock options granted in previous years, including 2,223 options at $37.53 (expiring 05/28/2027), 3,714 options at $40.9 (expiring 06/02/2028), 13,882 options at $8.1 (expiring 06/10/2029), and 8,353 options at $14.82 (expiring 08/10/2033).
- Additionally, he holds 11,336 restricted stock units that vest with no expiration.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options and restricted stock units by a director suggests confidence in the company's future, but it's a routine transaction.
Positives
- The acquisition of stock options and restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements, but the acquisition of stock options and restricted stock units suggests an expectation of future value appreciation.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions. Monitoring these filings can offer insights into management's sentiment and expectations for the company's performance.
Comparison to Industry Standards
- Stock option and RSU grants are common forms of executive compensation in publicly traded companies, particularly in the biotech and healthcare sectors.
- Companies like Exact Sciences (EXAS) and Guardant Health (GH) also utilize stock options and RSUs as part of their compensation packages to align management's interests with those of shareholders.
- The vesting schedules and exercise prices are generally in line with industry standards, designed to incentivize long-term performance.
Stakeholder Impact
- The acquisition of stock options and restricted stock units by a director can have a minor positive impact on shareholder sentiment.
- It aligns the director's interests with those of the shareholders, incentivizing them to work towards increasing the company's value.
Key Dates
| Date | Description |
|---|---|
| 05/28/2021 | Grant date of stock options with an exercise price of $37.53, expiring on 05/28/2027 |
| 06/02/2022 | Grant date of stock options with an exercise price of $40.9, expiring on 06/02/2028 |
| 06/10/2023 | Grant date of stock options with an exercise price of $8.1, expiring on 06/10/2029 |
| 06/01/2024 | Date of transaction: acquisition of stock options and restricted stock units |
| 06/01/2025 | Start date for exercisability of the newly acquired stock options and vesting of restricted stock units |
| 08/10/2024 | Grant date of stock options with an exercise price of $14.82, expiring on 08/10/2033 |
| 05/28/2027 | Expiration date of stock options with an exercise price of $37.53 |
| 06/02/2028 | Expiration date of stock options with an exercise price of $40.9 |
| 06/10/2029 | Expiration date of stock options with an exercise price of $8.1 |
| 08/10/2033 | Expiration date of stock options with an exercise price of $14.82 |
| 06/01/2034 | Expiration date of the newly acquired stock options |
| 06/04/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.